NCT03884829View on ClinicalTrials.gov

A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

November 29, 2021

Study Completion Date

October 19, 2023

Conditions
AML, AdultMyelodysplastic SyndromesALL, AdultCML, RefractoryCLL, Refractory
Interventions
DRUG

CYC140

CYC140 single agent

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT03884829 - A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | Biotech Hunter | Biotech Hunter